Triggered RNAi Therapy Using Metal Inorganic Nanovectors.


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
05 08 2019
Historique:
pubmed: 13 6 2019
medline: 26 6 2020
entrez: 13 6 2019
Statut: ppublish

Résumé

The administration of small interfering RNA (siRNA) is a very interesting therapeutic option to treat genetic diseases such as Alzheimer's or some types of cancer, but its effective delivery still remains a challenge. Herein, Au nanorod (GNR)-based platforms functionalized with polyelectrolyte layers were developed and analyzed as potential siRNA nanocarriers. The polymeric layers were successfully assembled on the particle surfaces by means of the layer-by-layer assembly technique through the alternating deposition of oppositely charged poly(styrene)sulfonate, PSS, poly(lysine), PLL, and siRNA biopolymers, with a final hyaluronic acid layer in order to provide the nanoconstructs with a potential targeting ability as well as colloidal stability in physiological medium. Once the hybrid nanocarriers were obtained, the cargo release, their colloidal stability in physiological-relevant media, cytotoxicity, cellular internalization and uptake, and knockdown activity were studied. The present hybrid particles release the genetic material inside cells by means of a protease-assisted and/or a light-triggered release mechanism in order to control the delivery of the oligonucleotides on demand. In addition, the hybrid nanovectors were observed to be nontoxic to cells and could efficiently deliver the genetic material in the cell cytoplasms. The GNR-based nanocarriers proposed here can provide a suitable environment to load and protect a sufficient amount of the genetic material to allow an efficient and sustained knockdown gene expression for long (up to 93% for 72 h), thanks to the slow degradation of PLL, without the observation of adverse side toxic effects. It was also found that the silencing activity was enhanced with the number of siRNA layers assembled in the nanoplatforms.

Identifiants

pubmed: 31188622
doi: 10.1021/acs.molpharmaceut.9b00021
doi:

Substances chimiques

Drug Carriers 0
Polystyrenes 0
RNA, Small Interfering 0
Green Fluorescent Proteins 147336-22-9
Polylysine 25104-18-1
polystyrene sulfonic acid 70KO0R01RY
Gold 7440-57-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3374-3385

Auteurs

Víctor X Mosquera (VX)

Departamento de Cirugía Cardíaca, Complexo Hospitalario Universitario A Coruña , Instituto de Investigación Biomédica de A Coruña (INIBIC) , 15006 A Coruña , Spain.

Alberto Bouzas (A)

Departamento de Cirugía Cardíaca, Complexo Hospitalario Universitario A Coruña , Instituto de Investigación Biomédica de A Coruña (INIBIC) , 15006 A Coruña , Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH